Drug startups coalesce around condensates

Elie Dolgin • February 9, 2021

Once a neglected biological phenomenon, condensates are attracting interest from small companies and large pharmas.

Three startups debuted in late 2020, all aiming to treat disease by manipulating the physiochemical and regulatory processes in cells that drive membrane-less hubs associated with disease pathogenesis. The field’s frontrunner, Dewpoint Therapeutics, also signed a major research pact last month with Pfizer — Dewpoint’s third such deal with a large pharma partner since the company’s inception two years ago.


Continue reading at Nature Biotechnology.

Girl jumping with arms bandaged
By Elie Dolgin August 27, 2025
Fresh treatments shift the focus from symptom management to repair.
By Elie Dolgin August 27, 2025
Smart algorithms take aim at antimicrobial resistance.